MD and pain specialist Tina Horsted from Horsted Institute and DanCann Pharma have started an ambitious observational study, which aims to raise awareness of the potentially beneficial effects of treatment with medical cannabis.

The study aims to supply further knowledge among general practitioners, who hesitate to prescribe medical cannabis to their patients and to adequately equip the medical profession in relation to knowledge of treatment, effect, and side effects. One of the challenges in this context is the still missing documentation of the impact of medical cannabis, and the Horsted Institute project must help to provide this.

Tina Horsted, MD and pain specialist from Horsted Institute, comments:

- We contacted several associations to find a number of candidates who were willing to participate in a course of treatment with medical cannabis. The interest was overwhelming, and we have now started the first 20 patients - and will start 10 more in September. The patients are all plagued by pain of varying intensity, and for the most part, are already being treated with painkillers. The goal of our study is to investigate whether medical cannabis can fully or partially help patients to a life where severe pain is not the limiting factor.

All the participants in the observation study are equipped with an Apple Watch, on which they enter their level of pain, nausea, and headache when they feel one or more of the symptoms into an app developed by Shape A/S, which is also a partner in the project. The data is registered directly in the patient record of Tina Horsted, who is the only one with access to sensitive personal information for GDPR reasons. For everyone else, the information is anonymized.

Tina Horsted elaborates:

- It is very important to show that medical cannabis has a positive influence on "secondary effects" - usually defined as "quality of life". That is why we also place great emphasis on data such as sleep patterns, level of activity, level of training and ECG, all of which are data points that the watches send automatically. We therefore expect to be able to show that, although medical cannabis may not have a direct healing effect on the indication itself, in most cases it helps to relieve the patient's pain, so that he/she sleeps better, moves more and generally gets an increased quality of life, says Tina Horsted.

CEO of DanCann Pharma Jeppe Krog Rasmussen is looking forward to following the patient project, which runs from now and will end in November, with the opportunity to continuously follow positive or negative trends in the process.

Jeppe Krog Rasmussen comments:

- In the industry, we have missed similar measures that can help shed light on and inform about the effects of treatment with medical cannabis. Through Project Horsted Digital, we get access to validated data, and we hope to be able to shed light on the fact that medical cannabis can help a large number of patients as an alternative for the many who have been given up on by the system when it comes to conventional treatment methods. 80% of the people who are treated with medical cannabis obtain the products on the illegal market, where there is no guarantee for product and contents. The industry, together with politicians and NGOs, needs to change this, and an important step on the way is more and better documentation. And hopefully more doctors will be willing to give medical cannabis a chance based on this. That is the goal.

About the Horsted Institute

The Horsted Institute was created with a vision to give people suffering from chronic pain and cancer, with accompanying symptoms in the form of sleep disorders, depression, PTSD, nausea, lack of appetite and/or weight loss, a better everyday life and a higher quality of life through symptom-relieving treatment. We believe that medical cannabis and cannabis-based medicine can be one of the best alternative forms of treatment.

Tina Horsted has over 30 years of experience in treating patients. 10 years as a general nurse and nurse anesthetist, then 20 years as a doctor, senior doctor and specialist in anesthesiology, intensive care medicine and pain management. She has taught both doctors and nurses, been a mentor for ward-doctors and lectured at courses and medical congresses in Denmark and abroad.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.